GlaxoSmithKline Pharmaceuticals Fair Value
GlaxoSmithKline Pharmaceuticals (GLAXO) average fair value is ₹400.76 across 9 valuation models — P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹2838.8 (-85.88%), fair value range ₹134.14–₹1038.69. Browse GLAXO financial statements for revenue, profit, balance sheet and cash flow data.
Fair Value Analysis Export
GLAXO Fair Value vs Current Price — Valuation Summary
GLAXO average fair value, fair value range, price gap and valuation status across 9 models: P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). Read GlaxoSmithKline Pharmaceutical dividend policy for the complete payout history and dividend yield track record.
P/E Based Valuation
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
Earnings Growth Model (PEG)
Peter Lynch Fair Value
Benjamin Graham Number
Discounted Cash Flow (DCF)
GLAXO Fair Value Analysis — Data Sources & Coverage
GlaxoSmithKline Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit GlaxoSmithKline Pharmaceutical share price chart.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
GLAXO vs Healthcare Sector Peers — P/E, P/B & Market Cap
GlaxoSmithKline Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.